Commentary Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness

被引：1
|
作者：
Cavalli, Giulio
Dagna, Lorenzo [1 ,2 ]
机构：
[1] Ist Sci San Raffaele, IRCCS, Unit Immunol Rheumatol Allergy & Rare Dis, Via Olgettina 60, I-20132 Milan, Italy
[2] Univ Vita Salute San Raffaele, Via Olgettina 60, I-20132 Milan, Italy
来源：
EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2020年 / 82卷
关键词：
D O I：
10.1016/j.ejim.2020.10.023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [11] Cost-effectiveness analysis on COVID-19 surveillance strategy of large-scale sports competition
    Xuechun Wang
    Yiru Cai
    Bo Zhang
    Xiangyu Zhang
    Lianhao Wang
    Xiangyu Yan
    Mingchen Zhao
    Yuan Zhang
    Zhongwei Jia
    Infectious Diseases of Poverty, 11
  • [12] Cost-effectiveness analysis on COVID-19 surveillance strategy of large-scale sports competition
    Wang Xuechun
    Cai Yiru
    Zhang Bo
    Zhang Xiangyu
    Wang Lianhao
    Yan Xiangyu
    Zhao Mingchen
    Zhang Yuan
    Jia Zhongwei
    贫困所致传染病（英文）, 2022, 11 (02) : 53 - 62
  • [13] Effectiveness of the second COVID-19 booster against Omicron: a large-scale cohort study in Chile
    Jara, Alejandro
    Cuadrado, Cristobal
    Undurraga, Eduardo A.
    Garcia, Christian
    Najera, Manuel
    Bertoglia, Maria Paz
    Vergara, Veronica
    Fernandez, Jorge
    Garcia-Escorza, Heriberto
    Araos, Rafael
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [14] Bias in observational studies on the effectiveness of hydroxychloroquine in COVID-19
    Hempenius, Mirjam
    Groenwold, Rolf H. H.
    de Boer, Anthonius
    Klungel, Olaf H.
    Gardarsdottir, Helga
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 561 - 561
  • [15] Risks of chloroquine or hydroxychloroquine use for COVID-19
    Reactions Weekly, 2020, 1808 (1) : 5 - 5
  • [16] Risks of hydroxychloroquine use for COVID-19 prophylaxis
    Sachdeva, Muskaan
    Shah, Monica
    Ziv, Michael
    Leshem, Eyal
    Dodiuk-Gad, Roni P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : E73 - E74
  • [17] Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
    Kaur, Amritpal
    Chaudhary, Gaurav
    Singh, Pargat
    Arora, Sandeep
    Kaur, Rajwinder
    CURRENT DRUG TARGETS, 2021, 22 (13) : 1536 - 1547
  • [18] Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19
    Gevers, S.
    Kwa, M. S. G.
    Wijnans, E.
    van Nieuwkoop, C.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (09) : 1276 - 1277
  • [19] Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection
    Meriglier, Etienne
    Rivoisy, Claire
    Hessamfar, Mojgan
    Bernard, Noelle
    Aureau, Ines
    Lapoirie, Joelle
    Contis, Anne
    Sacher, Frederic
    Sacristan, Benjamin
    Lahouati, Marin
    Pedeboscq, Stephane
    Vandenhende, Marie-Anne
    Bouchet, Stephane
    Bonnet, Fabrice
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (02) : 482 - 486
  • [20] Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis
    Faruqui, Atiya R.
    Xavier, Denis
    Kamat, Sandhya K.
    Chandy, Sujith J.
    Medhi, Bikash
    Tripathi, Raakhi K.
    Shetty, Yashashri C.
    Raj, John Michael
    Kaushal, Sandeep
    Balakrishnan, S.
    Atal, Shubham
    Tripathi, Santanu K.
    Badyal, Dinesh K.
    Dikshit, Harihar
    Roy, Sukalyan Saha
    Trivedi, Niyati
    Chatterjee, Suparna
    Desai, Chetna
    Tripathi, C. D.
    Rege, Nirmala N.
    Gupta, Pooja
    Raveendran, R.
    Kaul, Rajni
    Kshirsagar, Nilima A.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2021, 153 (1-2) : 219 - 226
12345